1. Regulatory T cells inhibit Fas ligand-induced innate and adaptive tumour immunity
- Author
-
Kate Louise Wright, Hannah E. Richards, Gareth James Betts, Emma Jones, Andrew James Godkin, Awen Gallimore, Anna Katharina Simon, and Gavin R. Screaton
- Subjects
Fas Ligand Protein ,T cell ,Immunology ,Melanoma, Experimental ,chemical and pharmacologic phenomena ,T-Lymphocytes, Regulatory ,Fas ligand ,Immunomodulation ,Mice ,03 medical and health sciences ,0302 clinical medicine ,Immune system ,Cell Line, Tumor ,medicine ,Animals ,Immunology and Allergy ,IL-2 receptor ,Cells, Cultured ,030304 developmental biology ,Mice, Knockout ,0303 health sciences ,Innate immune system ,biology ,Tumor Necrosis Factor-alpha ,hemic and immune systems ,Regulatory T cells ,Acquired immune system ,Immunity, Innate ,3. Good health ,Innate tumour immunity ,Mice, Inbred C57BL ,Immunity, Active ,medicine.anatomical_structure ,biology.protein ,Tumor necrosis factor alpha ,Antibody ,030215 immunology - Abstract
CD4+CD25+ regulatory T cells (Treg) are known to influence T cell responses to tumours. Here we have explored the role of Treg in inhibiting not only adaptive, but also innate immune responses to tumours. To this end we used a Fas ligand (FasL)-expressing melanoma cell line in a mouse model. In this system, innate immunity is sufficient to reject the tumour. All mice depleted of Treg and challenged with FasL-expressing melanoma remained tumour-free. Investigation of the underlying cellular effector mechanisms revealed that depletion of Treg enhanced an NK cell response capable of tumour lysis. Furthermore, this initial innate immune response primed mice to make an effective adaptive immune response leading to complete rejection of challenge with the parental melanoma. Both antigen-specific antibody and CD4+ T cells were implicated in protection via adaptive immunity. We conclude that removal of Treg and vaccination with whole tumour cells expressing FasL activates multiple arms of the immune system, leading to efficient tumour rejection. These findings highlight a novel role for FasL in inducing innate immune responses that are normally inhibited by Treg and uncover an adjuvant effect of FasL that can be used to stimulate tumour immunity after depletion of Treg.
- Published
- 2016
- Full Text
- View/download PDF